Ramón
García Sanz
Profesor Titular de Universidad
Hospital Universitario de la Princesa
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (12)
2023
-
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper
Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25
2022
-
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Blood cancer journal, Vol. 12, Núm. 4, pp. 68
-
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550
2021
-
Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC
Revista Espanola de Cardiologia, Vol. 74, Núm. 5, pp. 438-448
2019
-
Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations
Revista Espanola de Cardiologia, Vol. 72, Núm. 9, pp. 749-759
2013
-
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma: Results from a GEM/PETHEMA study
British Journal of Haematology, Vol. 163, Núm. 5, pp. 581-589
2012
-
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series
Leukemia and Lymphoma, Vol. 53, Núm. 5, pp. 812-819
2010
-
Amolecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma
Blood, Vol. 116, Núm. 8
-
Utilización de bisfosfonatos en pacientes con mieloma múltiple: recomendaciones del comité de expertos del Grupo Español de Mieloma del Programa Español de Tratamientos en Hematología
Medicina Clinica, Vol. 134, Núm. 6, pp. 268-278
2008
-
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression
Haematologica, Vol. 93, Núm. 4, pp. 560-565
-
Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: The prognostic impact of achieving molecular response
British Journal of Haematology, Vol. 142, Núm. 5, pp. 766-774
2006
-
Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma
Hematological Oncology, Vol. 24, Núm. 4, pp. 205-211